Maxvax has pioneered three technological platforms: recombinant protein, adjuvants, and mRNA, aimed at treating infectious diseases, cancer, and allergies.Learn more
Utilizing our technology platforms, we have developed a diverse pipeline of prophylactic and therapeutic vaccines to combat global health burdens.Learn more
We have constructed over 200,000 sq ft of state-of-the-art R&D and manufacturing facilities to support our pipeline, enabling us to handle product development all the way to industrial scale manufacturing, all in-house.Learn more...
Maxvax has received funding from the Bill & Melinda Gates Foundation to support the development of a low-cost HPV therapeutic vaccine candidate, aligning with global efforts to address the challenges posed by HPV infection that can lead to cervical cancer.more >
On September 13th, 2023, the Global Health Vaccine Adjuvant Webinar, which was hosted by Global Vaccine and Immunization Research Forum (GVIRF), was successfully held. Maxvax was the only innovative vaccine company in China that was invited to attend the virtual seminar. On the meeting, Maxvax’s founder and CEO Dr. Dexiang Chen gave a presentation on Enhancing Public Health Capacity: Strengthening the Global Availability, Accessibility, and Affordability of Adjuvants and Formulations, and took part in the keynote discussion.more >
On May 6, 2023, the kick-off meeting for the Phase II clinical study of Maxvax’s Recombinant Herpes Zoster Vaccine (CHO Cell) Biotechnology was successfully held in China’s northern province of Henan, and the enrollment was scheduled to be initiated on the next day.more >